Illumina provides tools and services to analyze genetic material with life science and clinical lab applications... Show more
Illumina maintains a leading position in the DNA sequencing and genomics industry, holding a substantial market share in next-generation sequencing platforms. The company’s competitive advantages stem from its established ecosystem of instruments, consumables, and software, including the high-throughput NovaSeq X series and data analysis tools such as DRAGEN. Strategic focus on clinical applications, multiomics integration, and artificial intelligence (AI)-enhanced data interpretation positions Illumina to capture growth in precision health. Medium-term expansion centers on transitioning research customers to clinical settings while addressing structural challenges such as instrument placement cycles and consumables recurring revenue stability.
Upcoming earnings releases will provide updates on 2026 guidance execution and clinical volume ramp. Product launches and enhancements, including expanded multiomics solutions and long-read sequencing capabilities, could drive adoption in research and clinical markets. Regulatory and reimbursement developments for minimal residual disease (MRD) testing and comprehensive genomic profiling (CGP) represent meaningful catalysts for clinical revenue growth. Analyst rating revisions and price-target adjustments, such as recent upgrades from firms including Guggenheim and RBC Capital, may influence sentiment; current consensus reflects a Hold rating with targets implying potential downside from recent levels, though select firms maintain Buy ratings.
The genomics sector benefits from accelerating adoption of precision medicine and declining sequencing costs, though it remains sensitive to broader healthcare expenditure patterns. Interest rate environments affect biotech research funding and capital allocation, while inflation influences instrument and consumables pricing dynamics. Geopolitical factors, including trade policies, could impact international revenue, particularly in research and applied markets. Regulatory climate surrounding data privacy, reimbursement for NGS-based tests, and AI integration in diagnostics will shape long-term accessibility and growth trajectories for Illumina’s offerings.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality. Explore the Trend Prediction Engine for additional insights.
Looking to 2026 and beyond, Illumina’s trajectory hinges on sustained clinical market penetration, continued NovaSeq X adoption, and multiomics platform expansion. Long-term structural drivers include market expansion in precision health, evolution toward higher-margin clinical consumables, and technology transitions incorporating AI and multiomic data layers. Margin sustainability will depend on operating leverage from volume growth and cost discipline. Competitive threats from alternative sequencing providers and regulatory developments around genomic testing reimbursement remain key variables. Capital allocation priorities, including share buybacks and research investments, could support shareholder value if aligned with clinical strategy execution. Consensus analyst expectations reflect cautious optimism on long-term genomics demand, tempered by valuation considerations relative to growth forecasts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a manufacturer of integrated systems for the analysis of genetic variation and function
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, ILMN has been loosely correlated with BRKR. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ILMN jumps, then BRKR could also see price increases.
| Ticker / NAME | Correlation To ILMN | 1D Price Change % | ||
|---|---|---|---|---|
| ILMN | 100% | +3.68% | ||
| BRKR - ILMN | 60% Loosely correlated | +4.43% | ||
| RVTY - ILMN | 58% Loosely correlated | +0.89% | ||
| AZTA - ILMN | 51% Loosely correlated | +1.59% | ||
| BIO - ILMN | 50% Loosely correlated | +1.17% | ||
| A - ILMN | 49% Loosely correlated | +0.58% | ||
More | ||||
ILMN's Aroon Indicator triggered a bullish signal on June 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 187 similar instances where the Aroon Indicator showed a similar pattern. In of the 187 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on June 15, 2026. You may want to consider a long position or call options on ILMN as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ILMN advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for ILMN moved out of overbought territory on June 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 69 cases where ILMN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ILMN turned negative on June 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ILMN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ILMN broke above its upper Bollinger Band on May 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. ILMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.434) is normal, around the industry mean (12.352). P/E Ratio (30.344) is within average values for comparable stocks, (140.644). ILMN's Projected Growth (PEG Ratio) (2.928) is slightly higher than the industry average of (1.521). ILMN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (5.879) is also within normal values, averaging (7.460).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ILMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.